Fate Therapeutics, Inc. (FATE)

Price$1.39

Favorite Metrics

Price vs S&P 500 (26W)-23.73%

Price vs S&P 500 (4W)16.87%

Market Capitalization$158.12M

All Metrics

Book Value / Share (Quarterly)$1.80

P/TBV (Annual)0.48x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-58.98%

Cash Flow / Share (Quarterly)$-0.97

Price vs S&P 500 (YTD)37.32%

Net Profit Margin (TTM)-2051.08%

EPS (TTM)$-1.15

10-Day Avg Trading Volume1.45M

EPS Excl Extra (TTM)$-1.15

Revenue Growth (5Y)-26.71%

EPS (Annual)$-1.15

ROI (Annual)-65.79%

Net Profit Margin (5Y Avg)-868.65%

Cash / Share (Quarterly)$1.77

Revenue Growth QoQ (YoY)-26.40%

ROA (Last FY)-42.74%

Revenue Growth TTM (YoY)-51.24%

EBITD / Share (TTM)$-1.13

ROE (5Y Avg)-51.48%

Operating Margin (TTM)-2222.45%

Cash Flow / Share (Annual)$-0.97

P/B Ratio0.76x

P/B Ratio (Quarterly)0.55x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)16.78x

Net Interest Coverage (TTM)-2.83x

ROA (TTM)-38.05%

EPS Incl Extra (Annual)$-1.15

Current Ratio (Annual)5.79x

Quick Ratio (Quarterly)5.69x

3-Month Avg Trading Volume1.58M

52-Week Price Return32.38%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.09

P/S Ratio (Annual)23.79x

Asset Turnover (Annual)0.02x

52-Week High$1.94

Operating Margin (5Y Avg)-954.74%

EPS Excl Extra (Annual)$-1.15

CapEx CAGR (5Y)3.84%

Tangible BV CAGR (5Y)44.36%

26-Week Price Return-14.98%

Quick Ratio (Annual)5.69x

13-Week Price Return28.70%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)5.79x

Enterprise Value$111.49

Revenue / Share Growth (5Y)-31.89%

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-16.35%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-2051.08%

Cash / Share (Annual)$1.77

3-Month Return Std Dev79.97%

Net Income / Employee (TTM)$-1

ROE (Last FY)-65.79%

Net Interest Coverage (Annual)-2.02x

EPS Basic Excl Extra (Annual)$-1.15

Receivables Turnover (TTM)2.58x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.15

Receivables Turnover (Annual)2.58x

ROI (TTM)-55.02%

P/S Ratio (TTM)23.79x

Pretax Margin (5Y Avg)-868.65%

Revenue / Share (Annual)$0.06

Tangible BV / Share (Annual)$4.97

Price vs S&P 500 (52W)-2.71%

Year-to-Date Return41.46%

5-Day Price Return6.11%

EPS Normalized (Annual)$-1.15

ROA (5Y Avg)-35.95%

Net Profit Margin (Annual)-2051.08%

Month-to-Date Return15.83%

Cash Flow / Share (TTM)$-1.58

EBITD / Share (Annual)$-1.13

Operating Margin (Annual)-2222.45%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-51.48%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.15

P/TBV (Quarterly)0.58x

P/B Ratio (Annual)0.55x

Pretax Margin (TTM)-2051.08%

Book Value / Share (Annual)$1.80

Price vs S&P 500 (13W)25.84%

Beta2.24x

Revenue / Share (TTM)$0.06

ROE (TTM)-55.02%

52-Week Low$0.91

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

3.89

Industry Peers — Biological Products(88)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
FATEFate Therapeutics, Inc.	23.79x	-51.24%	—	—	$1.39
AMGNAmgen Inc	5.20x	9.95%	73.30%	2.93%	$350.16
GILDGilead Sciences Inc	5.71x	2.40%	78.83%	133.64%	$135.87
ARGXargenx SE American Depositary Shares	12.59x	89.56%	150.91%	—	$834.45
BNTXBioNTech SE American Depositary Share	9.06x	-11.81%	84.21%	—	$105.19
BIIBBiogen Inc. Common Stock	2.72x	2.22%	75.69%	-18.77%	$183.34
MRNAModerna, Inc. Common Stock	10.91x	-39.93%	70.32%	—	$54.59
NBIXNeurocrine Biosciences Inc	4.64x	21.45%	98.18%	2.31%	$131.59
EXELExelixis Inc	4.89x	6.85%	96.39%	31.10%	$43.61
TECHBio-Techne Corp.	7.72x	1.64%	66.60%	-20.58%	$60.58
IBRXImmunityBio, Inc. Common Stock	74.42x	668.31%	99.34%	—	$8.20

About

Fate Therapeutics is a clinical-stage biopharmaceutical company developing cell-based immunotherapies targeting cancer and autoimmune disorders. The platform uses engineered natural killer and T cells derived from clonal master iPSC lines, alongside immunoregulatory candidates designed to prevent serious treatment complications.